Arena Announces Secondary Stock Worth $150M (revised)
Zacks Investment Research | Jul 17, 2017 03:11AM ET
Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA) shares jumped over 40% on Jul 11, after the company announced that a phase II study, evaluating its pipeline candidate ralinepag for treatment of pulmonary arterial hypertension (PAH), has met its primary endpoints.
However, the company’s shares declined 1% in after-hours trading on Tuesday, post its announcement that funds will be raised through an underwritten public offering.
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions. The underwriters are expected to be granted with an option to buy up to 22.5 million additional common shares after deducting the underwriting discounts and commissions to cover over-allotments. The completion or the actual size or terms of the offering were not made public by the company.
Citigroup (NYSE:C), Leerink Partners, Cantor Fitzgerald & Co. and UBS Investment Bank are serving as joint book-running managers for the public offering.
Arena’s shares have significantly outperformed the Zacks classified Medical-Biomed/Genetics industry so far this year. Shares of the company surged 83.1%, while the industry registered an increase of 7.1%.
Top line data from the phase II study on ralinepag has demonstrated a statistical significance for the candidate in improving pulmonary vascular resistance (PVR) compared with placebo.
Notably, PVR worsened from baseline in patients who were given a placebo. On the contrary, treatment with ralinepag resulted in an improvement of 29.8% in PVR compared with placebo and 20.1%, when compared with baseline. It has also come up with numerical improvement in patient’s ability to exercise as measured by a six-minute walk distance test.
The company has also said that the positive data from the study paves way for an expedited initiation of a phase III program.
The company has been facing a marginal increase in cash burn rate after it decided to shift focus to its clinical pipeline of early to mid-stage candidates. At the end of Dec 2016, the company had roughly $90.7 million of cash and cash equivalents. However, the above mentioned public offering is expected to boost Arena’s cash position.
Arena Pharmaceuticals, Inc. Price
Arena Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Get The News You Want
Arena currently carries a Zacks Rank #2 (Buy). Few other stocks worth considering in the healthcare sector are Astrazeneca (LON:AZN) PLC (NYSE:AZN) , Enzo Biochem, Inc. (NYSE:ENZ) and Exelixis, Inc. (NASDAQ:EXEL) , each sporting a Zacks Rank #1 (Strong Buy). You can see .
Astrazeneca’s earnings per share estimates inched up from $1.84 to $1.85 for 2017 and from $1.83 to $1.89, over the last 60 days. The company has delivered positive earnings surprises in all the four trailing quarters with an average beat of 142.60%. Astrazeneca’s shares have rallied 21.6% so far this year.
Enzo’s loss per share estimates has narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 in the last 30 days. The company has delivered positive earnings surprises in all the last four quarters with an average beat of 55.83%. Shares of Enzo surged 61.1% so far this year.
Exelixis’s earnings per share estimates moved up from 17 cents to 18 cents for 2017 over the last 30 days. The company has delivered positive earnings surprises in all the four trailing quarters with an average beat of 512.11%. Exelixis’s shares have soared 70.4% so far this year.
(NOTE: We are reissuing this article to correct a mistake. The original article, issued July 12, 2017, should no longer be relied upon.)
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.